-
Posted by
Two Blokes Jun 5 -
Filed in
Stock
-
12 views
MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. (“SMPA”) announced today that Knight and SMPA's affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE\u00ae (relugolix/estradiol/norethindrone acetate), ORGOVYX\u00ae (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight will acquire certain mature products (the “Mature Products”, together with MYFEMBREE\u00ae, ORGOVYX\u00ae and vibegron, the “Products”). For the year ended March 2025, the Products generated C$11.2 million in revenue.
